Exact Sciences price target raised to $28 from $22 at JMP Securities JMP Securities increased its price target on Exact Sciences as the firm, after conducting channel checks, estimates that ColoGuard will sell for $375. The firm continues to recommend buying shares of the stock.
Exact Sciences price target raised to $23 from $21 at Canaccord Canaccord raised its price target on Exact Sciences to $23 from $21 following yesterday's announcement the Mayo Clinic will adopt Cologuard. The firm believes there is the potential for additional healthcare systems to come on board as the publicity raises awareness among primary care doctors. Canaccord keeps its Buy rating on shares of Exact Sciences.